Meng Xia, Bo Pang, Shaowei Yi, Xinjue Shan, Shizhe Deng, Yinan Qin, Tao Jiang, Hai Lu
{"title":"Moxibustion for COVID-19: a systematic scoping review.","authors":"Meng Xia, Bo Pang, Shaowei Yi, Xinjue Shan, Shizhe Deng, Yinan Qin, Tao Jiang, Hai Lu","doi":"10.1097/HM9.0000000000000044","DOIUrl":null,"url":null,"abstract":"<p><p>Moxibustion has been widely used in the prevention and treatment of COVID-19. However, there is no systematic review of current topics and clinical findings on moxibustion for COVID-19. We conducted this scoping review to systematically summarize and analyze the themes and findings of published articles, and to provide an overview of current knowledge and practice of moxibustion for COVID-19.</p><p><strong>Methods: </strong>PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, SinoMed, Wan Fang Data, and VIP databases were searched from inception until April 2022. The relevant data were presented through bar graphs, structured tables, and figures along with descriptive statistics and analysis. This scoping review was conducted based on the PRISMA-ScR Checklist.</p><p><strong>Results: </strong>A total of 76 articles were reviewed: 47 reviews, 19 clinical research studies, seven systematic reviews (all were protocols), and three guidelines. All the studies were conducted by Chinese researchers and published from January 1, 2020 to March 14, 2022. The feasibility of moxibustion in the prevention and treatment of mild or moderate COVID-19 is based on the consensus of therapeutic mechanisms and effectiveness. The most adopted approach was the suspended and gentle moxibustion, and the most frequently applied or recommended acupoints were found to be ST36, CV8, CV6, CV4, CV12, GV14, BL13, LI4, ST25, and LR3.</p><p><strong>Conclusions: </strong>As a convenient and safe traditional Chinese medicine (TCM) therapy with its specific feature, moxibustion has been significantly effective at ameliorating mild or moderate symptoms among COVID-19 patients. Further large-scale, well-designed research and international cooperation are still warranted in clinical evaluations of moxibustion.</p><p><strong>Graphical abstract: </strong>http://links.lww.com/AHM/A35.</p>","PeriodicalId":93856,"journal":{"name":"Acupuncture and herbal medicine","volume":"2 3","pages":"162-171"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9d/aa/hm9-2-162.PMC9746254.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acupuncture and herbal medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/HM9.0000000000000044","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/12/8 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Moxibustion has been widely used in the prevention and treatment of COVID-19. However, there is no systematic review of current topics and clinical findings on moxibustion for COVID-19. We conducted this scoping review to systematically summarize and analyze the themes and findings of published articles, and to provide an overview of current knowledge and practice of moxibustion for COVID-19.
Methods: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, SinoMed, Wan Fang Data, and VIP databases were searched from inception until April 2022. The relevant data were presented through bar graphs, structured tables, and figures along with descriptive statistics and analysis. This scoping review was conducted based on the PRISMA-ScR Checklist.
Results: A total of 76 articles were reviewed: 47 reviews, 19 clinical research studies, seven systematic reviews (all were protocols), and three guidelines. All the studies were conducted by Chinese researchers and published from January 1, 2020 to March 14, 2022. The feasibility of moxibustion in the prevention and treatment of mild or moderate COVID-19 is based on the consensus of therapeutic mechanisms and effectiveness. The most adopted approach was the suspended and gentle moxibustion, and the most frequently applied or recommended acupoints were found to be ST36, CV8, CV6, CV4, CV12, GV14, BL13, LI4, ST25, and LR3.
Conclusions: As a convenient and safe traditional Chinese medicine (TCM) therapy with its specific feature, moxibustion has been significantly effective at ameliorating mild or moderate symptoms among COVID-19 patients. Further large-scale, well-designed research and international cooperation are still warranted in clinical evaluations of moxibustion.
艾灸已广泛应用于新冠肺炎的预防和治疗。然而，目前还没有对艾灸治疗新冠肺炎的主题和临床发现进行系统综述。我们进行了这项范围界定审查，以系统地总结和分析已发表文章的主题和发现，并概述艾灸治疗COVID-19的当前知识和实践。方法：从成立到2022年4月，检索PubMed、Embase、Cochrane图书馆、Web of Science、中国国家知识基础设施、SinoMed、万方数据和VIP数据库。相关数据通过条形图、结构化表格和图表以及描述性统计和分析呈现。本范围审查基于PRISMA ScR检查表进行。结果：共审查了76篇文章：47篇综述、19项临床研究、7项系统综述（均为方案）和3项指南。所有研究均由中国研究人员进行，并于2020年1月1日至2022年3月14日发表。艾灸预防和治疗轻度或中度新冠肺炎的可行性是基于治疗机制和有效性的共识。最常用的方法是悬灸和温和灸，最常用或推荐的穴位是ST36、CV8、CV6、CV4、CV12、GV14、BL13、LI4、ST25和LR3，艾灸在改善新冠肺炎患者的轻度或中度症状方面显著有效。在艾灸的临床评估方面，仍需要进一步大规模、精心设计的研究和国际合作。图形摘要：http://links.lww.com/AHM/A35.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
